Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Verifine blood lancets were included in the list of pharmaceutical benefits by Dental and Pharmaceutical Benefit Agency

17 Jul 2018

On the 5th of June of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a decision regarding inclusion of Verifine blood lancets produced by Mediq Sverige AB for diabetic patients to monitor the blood glucose levels into the list of pharmaceutical benefits. The Verifine blood lancets were compared to the following similar devices from the group Y92EA01 (blood samples lancets):

  • Vitrex Soft Lancettes 32G (vnr 738200) with a price of SEK 0.21 per piece
  • BD Micro-Fine + Lancett (vnr 203313) which are no longer included in the pharmaceutical benefits

As the estimated device has the same function with the comparators and the applied price was estimated as appropriate, the TLV suggested to include Verifine blood lancets into the list of pharmaceutical benefits with a price of SEK 23 per package/SEK 0.23 per piece.

The decision would come into force on the 18th of June of 2018.

See full information in Swedish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.